Impact of Acetylsalicylic Acid on Perioperative Bleeding Complications in Deceased Donor Kidney Transplantation

Overview

Journal World J Urol

Specialty Urology

Date 2025 Jan 3

PMID 39751644

Authors

Frank Friedersdorff

Matthias Schulz

Sarah Weinberger

Scarlet Munayco Ramos

Bernhard Ralla

Lutz Liefeldt

Martin Kanne

Senem Sakar

Markus H Lerchbaumer

Thorsten Schlomm

Isabel Lichy

Robert Peters

Jacob Schmidt

Affiliations

Soon will be listed here.

Abstract

Purpose: The objective of this study was to evaluate the perioperative outcomes and complications associated with the use of acetylsalicylic acid (ASA) in deceased donor kidney transplantation (KTX), with a particular focus on bleeding events.

Methods: We retrospectively analyzed 157 kidney transplant recipients (KTRs) who underwent KTX at Charité Berlin, Department for Urology, between February 2014 and December 2017. Patients were divided into two groups: patients with ASA in their preoperative medication (Group A, n = 59) and patients without ASA use (Group B, n = 98). Data on demographic information, medical conditions, surgical details, and postoperative outcomes were analyzed. Complications were classified using the Clavien-Dindo classification. Statistical analyses included t-tests, chi-square tests, and multivariate logistic regression.

Results: Group A had significantly older donors (59.7 ± 12.9 years vs. 52.0 ± 14.1 years, p < 0.001) and a higher incidence of coronary artery disease (42.4% vs. 3.1%, p = 0.001). There were no significant differences in perioperative hemoglobin loss and perioperative bleeding events between the groups, but a tendency towards higher rates of intraoperative bleeding (15.3% vs. 8.2%, p = 0.17) and postoperative transfusions (22% vs. 13.3%, p = 0.15) in Group A. Mortality was higher in Group A (18.6% vs. 4.1%, p = 0.003), with one death attributed to a cardiac event. Kaplan-Meier analysis revealed significantly inferior overall survival for Group A (p = 0.02), but no significant difference in graft survival (p = 0.18).

Conclusion: ASA use is associated with a trend towards increased intraoperative bleeding and postoperative blood transfusion but does not significantly increase major postoperative bleeding complications. Careful perioperative monitoring of patients with ASA is recommended.

References

Herzog C, Asinger R, Berger A, Charytan D, Diez J, Hart R . Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011; 80(6):572-86. DOI: 10.1038/ki.2011.223. View

Cheungpasitporn W, Thongprayoon C, Mitema D, Mao M, Sakhuja A, Kittanamongkolchai W . The effect of aspirin on kidney allograft outcomes; a short review to current studies. J Nephropathol. 2017; 6(3):110-117. PMC: 5607969. DOI: 10.15171/jnp.2017.19. View

Grotz W, Siebig S, Olschewski M, Strey C, Peter K . Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. Transplantation. 2004; 77(12):1848-53. DOI: 10.1097/01.tp.0000129407.31494.45. View

Mayrdorfer M, Liefeldt L, Wu K, Rudolph B, Zhang Q, Friedersdorff F . Exploring the Complexity of Death-Censored Kidney Allograft Failure. J Am Soc Nephrol. 2021; 32(6):1513-1526. PMC: 8259637. DOI: 10.1681/ASN.2020081215. View

Benko T, Gottmann M, Radunz S, Bienholz A, Saner F, Treckmann J . One-year Allograft and Patient Survival in Renal Transplant Recipients Receiving Antiplatelet Therapy at the Time of Transplantation. Int J Organ Transplant Med. 2018; 9(1):10-19. PMC: 5839625. View

Clavien P, Barkun J, De Oliveira M, Vauthey J, Dindo D, Schulick R . The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009; 250(2):187-96. DOI: 10.1097/SLA.0b013e3181b13ca2. View

Eng M, Brock G, Li X, Chen Y, Ravindra K, Buell J . Perioperative anticoagulation and antiplatelet therapy in renal transplant: is there an increase in bleeding complication?. Clin Transplant. 2010; 25(2):292-6. DOI: 10.1111/j.1399-0012.2010.01293.x. View

Bellos I, Marinaki S, Lagiou P, Benetou V . Aspirin for the Primary Prevention of Cardiovascular Diseases in Patients with Chronic Kidney Disease: An Updated Meta-analysis. Am J Cardiovasc Drugs. 2024; 24(2):241-253. PMC: 10973060. DOI: 10.1007/s40256-024-00630-y. View

Cohen-Bucay A, Gordon C, Francis J . Non-immunological complications following kidney transplantation. F1000Res. 2019; 8. PMC: 6381799. DOI: 10.12688/f1000research.16627.1. View

10.

Lemoine M, Titeca Beauport D, Lobbedez T, Choukroun G, Hurault de Ligny B, Hazzan M . Risk Factors for Early Graft Failure and Death After Kidney Transplantation in Recipients Older Than 70 Years. Kidney Int Rep. 2019; 4(5):656-666. PMC: 6506713. DOI: 10.1016/j.ekir.2019.01.014. View

11.

Floege J, Schlieper G . Chronic kidney disease: How effective and safe are antiplatelet agents in CKD?. Nat Rev Nephrol. 2013; 9(6):314-6. DOI: 10.1038/nrneph.2013.83. View

12.

Lee T, DSouza K, Hameed A, Yao J, Lam S, Chadban S . Comparison of the effect of single vs dual antiplatelet agents on post-operative haemorrhage after renal transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando). 2021; 35(1):100594. DOI: 10.1016/j.trre.2020.100594. View

13.

Musetti C, Quaglia M, Cena T, Battista M, Fenoglio R, Lazzarich E . Impact of pre-transplant antiaggregant and anticoagulant therapies on early hemorrhagic and cardiovascular events after kidney transplantation. J Nephrol. 2015; 28(6):757-64. DOI: 10.1007/s40620-015-0185-1. View